CTLA4 and melanoma: <h4>Introduction</h4>Metastatic melanoma has historically had a poor prognosis; however, survival has improved with immunotherapies, such as PD-1 and CTLA-4 inhibitors, and molecular targeted therapies for BRAF-mutant tumors.